R. Castleberry

发表

Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.

A. Look, W. London, G. Brodeur, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.

John M Maris, Rani E George, A. Look, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.

A. Look, W. London, G. Brodeur, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of the extent of prophylactic regional lymph node radiotherapy on survival in high‐risk neuroblastoma: A report from the COG A3973 study

K. Matthay, D. von Allmen, L. Diller, 2019, Pediatric blood & cancer.

Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.

W. London, P. Thorner, R. Marcus, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting outcome in neuroblastoma.

R. Castleberry, 1999, The New England journal of medicine.

Lymph node sampling in localized neuroblastoma: a Pediatric Oncology Group study.

J. Shuster, F. A. Hayes, R. Castleberry, 1999, Journal of pediatric surgery.

The International Neuroblastoma Pathology Classification (the Shimada system)

K K Matthay, D O Stram, D. Stram, 1999, Cancer.

Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.

A. Look, G. Brodeur, S. Cohn, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group.

E. Halperin, R. Shamberger, D. Strother, 1997, European journal of cancer.

International criteria for diagnosis, staging and response to treatment in patients with neuroblastoma.

C. R. Pinkerton, B. Bernardi, A. Barrett, 1988, Progress in clinical and biological research.

Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.

A T Look, J J Shuster, A. Look, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myelopoiesis in immunologically classified subgroups of childhood acute lymphocytic leukemia.

H. Findley, W. Crist, R. Castleberry, 1980, Medical and pediatric oncology.

Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors.

P. Emanuel, R. Castleberry, R. Snyder, 2000, Blood.

Severe fletcher factor (plasma prekallikrein) deficiency with partial deficiency of hageman factor (factor xii): Report of a case with observation on in vivo and in vitro leukocyte chemotaxis

M. Moore, M. Poon, R. Castleberry, 1982, American journal of hematology.

Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia

P. Emanuel, Y. L. Liu, S. Meleth, 2005, Pediatric blood & cancer.

Mutations of the NF 1 Gene in Children With Juvenile Myelomonocytic Leukemia Without Clinical Evidence of Neurofibromatosis , Type 1

K. Shannon, L. Side, P. Emanuel, 1998 .

Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy.

K. Shannon, P. Emanuel, R. Castleberry, 1996, Molecular medicine today.

Chemotherapy for neuroblastoma: is it all or none?

J. Maris, R. Castleberry, 2003, Journal of pediatric hematology/oncology.

Do children benefit from mass screening for neuroblastoma? Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening

P. Prorok, A. Craft, W. Woods, 1991, The Lancet.

Results of Pediatric Oncology Group Protocol 8104 for Infants with Stages D and DS Neuroblastoma

J. Shuster, D. Strother, F. A. Hayes, 1995, Journal of pediatric hematology/oncology.

The risk of nephrectomy during local control in abdominal neuroblastoma.

R. Shamberger, F. A. Hayes, P. V. Rao, 1998, Journal of pediatric surgery.

Identification of nuclear tau isoforms in human neuroblastoma cells.

L. Binder, T. Howard, R. Castleberry, 1990, Proceedings of the National Academy of Sciences of the United States of America.

The cytosine arabinoside (Ara-C) syndrome.

W. Crist, R. Castleberry, T. Holbrook, 1981, Medical and pediatric oncology.

Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.

K K Matthay, A T Look, S L Cohn, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of association between abnormalities of the chromosome 9 short arm and either "lymphomatous" features or T cell phenotype in childhood acute lymphocytic leukemia.

A. Carroll, W. Crist, R. Castleberry, 1987, Blood.

Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors.

P. Emanuel, K. Zuckerman, R. Castleberry, 1991, Blood.

and Noonan Syndrome/myeloproliferative disease The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia

M. Loh, B. Gelb, M. Tartaglia, 2013 .

The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.

M. Loh, B. Gelb, M. Tartaglia, 2005, Blood.

A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia.

P. Emanuel, A. Homans, R. Castleberry, 1994, The New England journal of medicine.

Cell culture studies and oncogene expression in juvenile chronic myelogenous leukemia.

R. Parmley, R. Berkow, R. Castleberry, 1988, Experimental hematology.

patients with juvenile myelomonocytic leukemia Development of an allele-specific minimal residual disease assay for

M. Loh, A. Yoshimi, C. Niemeyer, 2013 .

Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia.

M. Loh, A. Yoshimi, C. Niemeyer, 2006, Blood.

The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia.

P. Emanuel, R. Castleberry, R. Gualtieri, 1991, Experimental hematology.

Dysgranulopoietic neutropenia and abnormal monocytes in childhood vitamin B12 deficiency

W. Crist, R. Castleberry, C. Holbrook, 1980, American journal of hematology.

Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG Phase II study.

A. Cantor, D. Strother, R. Castleberry, 1997, Journal of pediatric hematology/oncology.

Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study.

A. Cantor, A. Green, R. Berkow, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neuroblastoma: Effect of genetic factors on prognosis and treatment

A. Nakagawara, R. Seeger, G. Brodeur, 1992, Cancer.

Circulating immune complexes in childhood malignancies: a Pediatric Oncology Group study.

V. Land, R. Castleberry, D. Fernbach, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hereditary Pyropoikilocytosis and Elliptocytosis: Clinical, Laboratory, and Ultrastructural Features in Infants and Children

R. Parmley, J. Prchal, W. Crist, 1982, Pediatric Research.

Surgical resection alone is effective treatment for ovarian immature teratoma in children and adolescents: a report of the pediatric oncology group and the children's cancer group.

J. Cullen, R. Giller, M. Krailo, 1999, American journal of obstetrics and gynecology.

Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma.

J. Shuster, I. Smith, M. Wharam, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.

F. Berthold, A. Barrett, R. Seeger, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral complications in children with cancer.

A. Dasanayake, R. Castleberry, N. Childers, 1993, Oral surgery, oral medicine, and oral pathology.

SERUM LACTATE DEHYDROGENASE IN CHILDHOOD NEUROBLASTOMA

J. Shuster, R. Castleberry, E. I. Smith, 1992 .

tdic(9;12): A nonrandom chromosome abnormality in childhood B-cell precursor acute lymphoblastic leukemia: A pediatric oncology group study

F. Behm, S. Raimondi, M. Borowitz, 1987 .

Progress against childhood cancer: the Pediatric Oncology Group experience.

J. Krischer, L. Frankel, J. Shuster, 1992, Pediatrics.

Phase II Window Study of the Farnesyltransferase Inhibitor R115777 (Zarnestra®) in Untreated Juvenile Myelomonocytic Leukemia (JMML): A Children’s Oncology Group Study.

M. Loh, B. Widemann, P. Emanuel, 2005 .

Genetic analysis of childhood endodermal sinus tumors by comparative genomic hybridization.

Jie Hu, E. Perlman, R. Castleberry, 2000, Journal of pediatric hematology/oncology.

Mutations in GATA2 are rare in juvenile myelomonocytic leukemia.

M. Loh, K. Shannon, P. Emanuel, 2013, Blood.

are rare in juvenile myelomonocytic leukemia GATA2 Mutations in

M. Loh, P. Emanuel, Y. L. Liu, 2014 .

Cytosine arabinoside and 6‐thioguanine in the treatment of childhood acute myeloblastic leukemia

R. Castleberry, W. P. McCann, H. Moreno, 1977, Cancer.

Ocular late effects in childhood and adolescent cancer survivors: A report from the childhood cancer survivor study

Kayla L. Stratton, L. Robison, T. Kawashima, 2010, Pediatric blood & cancer.

Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.

A. Look, A. Cantor, G. Brodeur, 1997, Journal of the National Cancer Institute.

Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study.

C. Stolar, J. Cullen, R. Giller, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study.

W. London, A. L. Frazier, N. Marina, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.

W. London, E. Perlman, P. Colombani, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fibrolamellar hepatocellular carcinoma in children and adolescents

J. Quinn, E. Douglass, M. Sensel, 2003, Cancer.

Comparison of maintenance treatment regimens for first central nervous system relapse in children with acute lymphocytic leukemia. A pediatric oncology group study

G. Humphrey, T. Vats, S. Culbert, 1985, Cancer.

Outcomes of the POG 9340/9341/9342 trials for children with high‐risk neuroblastoma: A report from the Children's Oncology Group

Yang Zhang, W. London, P. Zage, 2008, Pediatric blood & cancer.

Biology and treatment of neuroblastoma.

R. Castleberry, R. P. Castleberry, 1997, Pediatric clinics of North America.

Serum Lactate Dehydrogenase in Childhood Neuroblastoma A Pediatric Oncology Group Recursive Partitioning Study

J. Shuster, G. Brodeur, T. Vietti, 1992, American journal of clinical oncology.

Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: a Pediatric Oncology Group Study.

A. Look, J. Krischer, Y. Ravindranath, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preradiation chemotherapy with methotrexate, cisplatin, 5‐fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma

G. Swanson, A. Pappo, C. Rodríguez-Galindo, 2005, Cancer.

Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1.

K. Shannon, L. Side, P. Emanuel, 1998, Blood.

Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.

B. Brumback, K. Matthay, L. Diller, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study.

A. Look, M. Valentine, V. Valentine, 2001, Neoplasia.

Changing trends of research and treatment in infant neuroblastoma

R. Castleberry, G. Friedman, 2007, Pediatric blood & cancer.

The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives.

F. Berthold, K. Matthay, L. Boni, 2005, Cancer letters.

Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.

A. Look, C. Alvarado, W. London, 2000, Journal of pediatric hematology/oncology.

Childhood liposarcoma. Report of a case and review of the literature

R. Castleberry, D. Kelly, W. Cain, 1984, Cancer.

Correlation between morphologic and other prognostic markers of neuroblastoma a study of histologic grade, DNA index, N‐myc gene copy number, and lactic dehydrogenase in patients in the pediatric oncology group

A. Look, J. Shuster, J. Silverman, 1993, Cancer.

Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study.

L. Robison, A. Mertens, J. Gurney, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PTEN deficiency is a common defect in juvenile myelomonocytic leukemia.

P. Emanuel, R. Castleberry, Yunying Liu, 2009, Leukemia research.

Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study.

J. Quinn, E. Douglass, M. Sensel, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II/III trial of a pre‐transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group

M. Loh, R. Arceci, T. Alonzo, 2015, Pediatric blood & cancer.

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.

A. Look, D. Stram, J. Maris, 2010, The New England journal of medicine.

Significance of chromosome 1p loss of heterozygosity in neuroblastoma.

A. Look, J. Shuster, J. Maris, 1995, Cancer research.

The international neuroblastoma risk groups (INRG): a preliminary report

F. Berthold, J. Shuster, D. Frappaz, 1997 .

Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.

J. Maris, K. Matthay, H. Shimada, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Age‐linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the pediatric oncology group

J. Shuster, E. W. Larkin, A. Cantor, 1992, Cancer.

Predictive ability of lukes‐collins classification for immunologic phenotypes of childhood non‐Hodgkin lymphoma: An institutional series and literature review

A. Flint, W. Crist, R. Castleberry, 1981, Cancer.

The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma.

J. Shuster, A. Cantor, R. Marcus, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Author's response to the comments on “PTEN deficiency is a common defect in juvenile myelomonocytic leukemia” [Leuk. Res. (2008) (Epub November 17)]

P. Emanuel, Y. L. Liu, R. Castleberry, 2009 .

Management of localized thoracic neuroblastoma.

W. Crist, R. Castleberry, T. Holbrook, 1979, Medical and pediatric oncology.

Successful Use of Plasma Exchange in a Child with Refractory Immune Hemolytic Anemia

R. Castleberry, E. Kohaut, J. Atchison, 1987, The American journal of pediatric hematology/oncology.

Postoperative treatment of nonmetastatic visible residual neuroblastoma: a Pediatric Oncology Group study.

J. Shuster, A. Green, F. A. Hayes, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Infants with neuroblastoma and regional lymph node metastases have a favorable outlook after limited postoperative chemotherapy: a Pediatric Oncology Group study.

J. Shuster, N. Winick, F. A. Hayes, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stage-specific expression of integrin alphaVbeta3 in neuroblastic tumors.

M. Arnold, C. Gladson, R. Castleberry, 1996, The American journal of pathology.

Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma.

W. London, Zhengjia Chen, K. Newman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group.

A. Olshan, A. Look, D. Stram, 1999, American journal of epidemiology.

Rapamycin -- a Potential Mechanistically Targeted Therapeutic for Juvenile Myelomonocytic Leukemia.

P. Emanuel, Y. L. Liu, R. Castleberry, 2004 .

Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Randomized Phase II study.

J. Shuster, A. Green, T. Vietti, 1995, Medical and pediatric oncology.

Juvenile chronic myelogenous leukemia.

J. Hess, P. Emanuel, R. Castleberry, 1996, American journal of clinical pathology.

Modified histologic grading of neuroblastomas by replacement of mitotic rate with Mitosis Karyorrhexis Index: A clinicopathologic study of 223 cases from the Pediatric Oncology Group

A. Cantor, R. Castleberry, G. Altshuler, 1996, Cancer.

Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. A clinicopathologic study of 213 cases from the pediatric oncology group

J. Shuster, E. W. Larkin, A. Cantor, 1992, Cancer.

Thoracic neuroblastoma: a Pediatric Oncology Group study.

J. Shuster, F. A. Hayes, R. Castleberry, 1993, Journal of pediatric surgery.

Biological variables in thoracic neuroblastoma: a Pediatric Oncology Group study.

A. Look, J. Morris, A. Cantor, 1995, Journal of pediatric surgery.

The Risk of Nephrectomy During Local Control in Abdominal Neuroblastoma

R. Shamberger, F. A. Hayes, P. V. Rao, 1999 .

Neuroblastoma and parental occupation

Kay Teschke, Daniel O. Stram, Andrew F. Olshan, 2004, Cancer Causes & Control.

Acute leukemia and hypopyon.

F. Elsas, W. Crist, R. Castleberry, 1978, The Journal of pediatrics.

Residential Pesticide Exposure and Neuroblastoma

K Teschke, D A Savitz, A T Look, 2001, Epidemiology.

Minority adult survivors of childhood cancer: a comparison of long-term outcomes, health care utilization, and health-related behaviors from the childhood cancer survivor study.

M. Hudson, L. Robison, A. Mertens, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Parental exposure to medical radiation and neuroblastoma in offspring.

Andrew F Olshan, A. Olshan, J. Neglia, 2004, Paediatric and perinatal epidemiology.

Conventional versus modified morphologic criteria for ganglioneuroblastoma. A review of cases from the Pediatric Oncology Group.

J. Shuster, E. W. Larkin, A. Cantor, 1996, Archives of pathology & laboratory medicine.

Translocation (6;9)(p23;q34) in acute nonlymphocytic leukemia: three new cases.

A. Carroll, R. Castleberry, W. Finley, 1985, Cancer genetics and cytogenetics.

Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification

A. Naranjo, J. Maris, W. London, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group.

J. Shuster, R. Castleberry, E. I. Smith, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations of the NF1 gene in leukemias from children without evidence of neurofibromatosis, type 1.

K. Shannon, L. Side, P. Emanuel, 1997 .

Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study.

A. Look, M. Valentine, G. Brodeur, 1995, Cancer research.

tdic(9;12): a nonrandom chromosome abnormality in childhood B-cell precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study.

S. Raimondi, M. Borowitz, A. Carroll, 1987, Blood.

Systematization of primary histopathologic and fine-needle aspiration cytologic features and description of unusual histopathologic features of neuroblastic tumors: a report from the Pediatric Oncology Group.

J. Shuster, J. Silverman, E. W. Larkin, 1993, Human pathology.